SLXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Silexion Therapeutics Corp (SLXN) is not a good buy for a beginner investor with a long-term strategy at this time. The stock lacks positive technical indicators, has weak financial performance, no significant news or catalysts, and no proprietary trading signals to support a buy decision.
The stock is currently in a bearish trend with MACD below 0 and negatively contracting, RSI in the neutral zone at 34.867, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.156 and 0.995, while resistance levels are at 1.675 and 1.835. Pre-market price is $1.39, up 6.11%, but this does not indicate a strong reversal.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
despite a 152.55% YoY improvement. EPS dropped significantly (-90.12% YoY). No recent congress trading data or influential figure activity.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but remains negative at -$4,412,000. EPS dropped sharply to -1.4, indicating worsening profitability. Gross margin is 0, showing no operational efficiency.
No data on analyst ratings or price target changes. Wall Street sentiment is neutral with no clear pros or cons.
